← Back to patent-cliff list
Amrubicin Hydrochloride
Tier C — Watch / tradeAmrubicin Hydrochloride
Sumitomo Dainippon Pharma Co Ltd
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP2
Brand：Amrubicin, Calsed
Indications (approved)：Non-small cell lung cancer, Small cell lung cancer
Regional status
US
No progress
2006-11-01
EU
No progress
2006-11-01
China
No progress
2008-04-17
Japan
Approved
2002-04-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amrubicin Hydrochloride?
Approved indications include: Non-small cell lung cancer, Small cell lung cancer.
When does the Amrubicin Hydrochloride patent expire?
No public expiry year is available for Amrubicin Hydrochloride yet; this page updates once verified.
How do I get a quote for Amrubicin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27